Concepedia

Author

Valentina Burgio

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

Burgio, Valentina, V. Burgio, Valentina Burgio

71

Publications

1.1K

Citations

20

H-Index

32

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoVita-Salute San Raffaele UniversityIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleIstituto Oncologico VenetoUniversity of Cagliari
VB

About

Valentina Burgio is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

366

2

Hepatology

8

8

304

3

Health Sciences

4

4

105

4

Engineering

1

1

21

5

Cell Biology

1

1

21

Valentina Burgio

×

31

Publications

916

Citations

20

H-Index

YearCitations

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima,

ESMO Open

2022

124

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada,

European Journal of Cancer

2022

123

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Mara Persano, Margherita Rimini, Toshifumi Tada,

European Journal of Cancer

2023

50

Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Margherita Rimini, Shigeo Shimose, Sara Lonardi,

Hepatology Research

2021

44

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

Margherita Rimini, Masatoshi Kudo, Toshifumi Tada,

ESMO Open

2021

43

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Andrea Casadei‐Gardini, Margherita Rimini, Masatoshi Kudo,

Liver Cancer

2022

37

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Valentina Burgio, Massimo Iavarone, G.G. Di Costanzo,

Cancer Management and Research

2021

35

Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Margherita Rimini, Mara Persano, Toshifumi Tada,

Journal of Cancer Research and Clinical Oncology

2023

35

The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma

Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini,

Hepatology Research

2022

29

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Mara Persano, Margherita Rimini, Toshifumi Tada,

Journal of Cancer Research and Clinical Oncology

2022

28

Page 1